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I read with great interest the article by Hermon and coworkers
[1], who reported that surfactant application in children with
severe respiratory failure treated with extracorporeal
membrane oxygenation was associated with improved lung
volume and pulmonary mechanics. Although these findings
must be confirmed in prospective studies, they are very
promising. Based on a series of animal studies, more than
10 years ago we advocated use of a combination of surfactant
therapy and extracorporeal life support in the treatment of
severe respiratory failure. We found that one effective option
is to combine intratracheal instillation of a large fluid volume
with diluted surfactant and LFV-ECCO2R (low frequency
ventilation and extracorporeal carbon dioxide removal).
In animal studies using 141Ce-labelled microspheres mixed
with the surfactant [2,3], we observed that, following
endotracheal administration, this surfactant preparation was
distributed inhomogeneously in the lungs. However,
significantly improved distribution was achieved when this
dose of surfactant (100 mg/kg body weight) was diluted with
normal saline to a concentration of 6.25 g/l. In order to apply
this dose, intratracheal fluid administration of 16.0 ml/kg body
weight was required. Subsequently, we evaluated the effect
of large volume fluid installation in lung lavaged rabbits while
applying two gas exchange techniques, namely continuous
positive  pressure ventilation and LFV-ECCO2R [4]. We
observed significantly higher arterial oxygen tension in the
LFV-ECCO2R group than in the control group in the
normocapnic state.
Based on these promising findings we further explored
weaning possibilities [5]. Four hours after surfactant
instillation in lung lavaged rabbits, the inspired fraction of
oxygen could be decreased to 40% in a stepwise manner,
such that arterial oxygen tension could easily be maintained
within the normal range. Extracorporeal flow rates during
perfusion ranged from 20 to 35 ml/kg per min and were
sufficient to keep the arterial carbon dioxide tension and pH
within normal limits. After 4 hours, the lung lavaged rabbits
could breathe spontaneously with continuous positive airway
pressure and 40% oxygen, and normal blood gas values were
maintained. Using LFV-ECCO2R we required flow rates of
only 20–35 ml/kg per min and were able to use a small,
compact circuit, thereby minimizing the additional adverse
effects of an extracorporeal circuit [6,7]. Our findings indicate
that barotrauma/volutrauma due to mechanical ventilation and
oxygen toxicity due to high fraction of inspired oxygen can be
minimized in an animal model of acute severe respiratory
failure using combined LFV-ECCO2R and surfactant therapy.
I hope that this additional information will stimulate the
authors to explore further the clinical application of surfactant
and extracorporeal life support.
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